Avantor, Inc. (AVTR)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Buy: pullback-to-support limit at 15.20 within an intact multi-week uptrend (price above SMA20/50/200 and EMA9/21; ADX 48.5 rising; RSI 69.7). Protective stop 14.74 below the 09-15 swing low (structural 15.10 widened to the 1.0xATR pullback floor), targets 16.12 (+2.0xATR) and 16.81 (+3.5xATR); R/R 2.00. No earnings/dividend blackout in effect; next confirmed earnings 2026-11-04 is outside the 15-day holding window; liquidity ~$107M 20-day average dollar volume.
Company overview
Avantor, Inc., founded in 1904 and headquartered in Radnor, Pennsylvania, provides essential products and specialized services globally. It serves industries such as biopharmaceuticals, healthcare, and advanced technology with a wide range of materials, consumables, and advanced equipment. The company also offers services like laboratory support, equipment maintenance, and biopharmaceutical material development.
Fundamental
fairAvantor shows solid cash generation and liquidity but faces revenue decline and margin pressure.
Score 3 (Mixed): Avantor remains cash-generative (FY2025 operating cash flow $624M vs. ~$129M capex) and liquid (10-Q 2026-06-30: $307M cash plus ~$1.38B unused revolver availability), but the core business has been shrinking and margins have eased (2021–2025 revenue CAGR ~-3%; adjusted EBITDA margin 16.3% in 2025 vs. 17.7% in 2024). The $785M goodwill impairment and resulting 2025 GAAP net loss underscore execution risk; valuation looks reasonable on EV/Sales (~1.9x) and free-cash-flow yield (~5.5%) but needs evidence of sustained stabilization for a higher score.
Sentiment
fairMedia sentiment has improved post-earnings, but no clear catalysts or retail engagement are evident.
Near-term tone improved after Avantor’s Q2 2026 earnings release (2026-07-29, announced), but the next-30-trading-day forward catalyst calendar looks thin and baseline coverage still flags destocking/execution risk. No regulator-confirmed investigations surfaced (only plaintiff-law-firm solicitation noise) and Reddit engagement is negligible, keeping conviction mid.
Technical
goodThe stock is in a strong uptrend with price above key moving averages and robust momentum indicators.
Strong multi-week uptrend: price 15.61 sits above all key moving averages (SMA20 14.73, SMA50 13.31, SMA200 10.50, EMA9 15.11, EMA21 14.64) with the MA stack in bullish order, and ADX 48.52 (rising) confirms a very strong directional move. Momentum is robust (RSI 69.70, Williams %R -12.58, MACD line +0.57 above zero) and volume is healthy (~$107M 20-day average dollar volume, ~$121M recent 3-session average). One weak signal: the MACD histogram is slightly negative (-0.01, line just below signal 0.58) and RSI is approaching overbought, so momentum is cooling near the highs. The entry is therefore structured as a pullback-to-support limit at 15.20 (near the 09-15 swing low of 15.19) rather than a breakout chase; structure-honest stop floored to 1.0x ATR per the pullback rule yields R/R 2.00. Score 4: strong setup with one weak (momentum-cooling) signal.
You’re looking at 2026-09-16 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

